Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Novo Nordisk had hoped that by mimicking multiple hormones, CagriSema would deliver greater weight loss. The drug combines semaglutide — the active ingredient in Ozempic and Wegovy — with ...